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Abstract
Normosmic congenital hypogonadotropic hypogonadism (nCHH) is a rare reproductive disease leading to lack of puberty
and infertility. Loss-of-function mutations of GNRH1 gene are a very rare cause of autosomal recessive nCHH. R31C GNRH1 is
the only missense mutation that affects the conserved GnRH decapeptide sequence. This mutation was identified in a CpG
islet in nine nCHH subjects from four unrelated families, giving evidence for a putative ‘‘hot spot’’. Interestingly, all the nCHH
patients carry this mutation in heterozygosis that strikingly contrasts with the recessive inheritance associated with frame
shift and non-sense mutations. Therefore, after exclusion of a second genetic event, a comprehensive functional
characterization of the mutant R31C GnRH was undertaken. Using different cellular models, we clearly demonstrate a
dramatic reduction of the mutant decapeptide capacity to bind GnRH-receptor, to activate MAPK pathway and to trigger
inositol phosphate accumulation and intracellular calcium mobilization. In addition it is less able than wild type to induce lh-
beta transcription and LH secretion in gonadotrope cells. Finally, the absence of a negative dominance in vitro offers a
unique opportunity to discuss the complex in vivo patho-physiology of this form of nCHH.
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Introduction
The gonadotropin-releasing hormone (GnRH) is essential in
mammalian reproduction. This decapeptide, released from
hypothalamic GnRH-neurons, triggers an intracellular cascade
involving IP3 accumulation, calcium mobilization and MAPK
phosphorylation through its cognate receptor GnRHR. The
activation of these signaling pathways ultimately stimulates the
synthesis and secretion of gonadotropins (LH and FSH) by
pituitary gonadotrope cells.
The decapeptide sequence is conserved among most mammals
and the amino and carboxyl termini are conserved in mammals
and invertebrates [1–4].
Mutations of the human GNRH1 gene, encoding a 92 amino-
acid pre-pro-GnRH, are a very rare cause of normosmic
congenital hypogonadotropic hypogonadism (nCHH). A frame
shift resulting in a failure to translate the GnRH peptide sequence
gives rise to nCHH with autosomal recessive inheritance [5].
Subsequently a p.R31C GNRH1 mutation in which arginine is
substituted by cysteine has been described [6,7]. This is the sole
mutation affecting the GnRH decapeptide sequence. The arginine
in position 8 of the GnRH decapeptide has been shown to be
crucial for biological activity [2–4] and shown to interact with an
acidic residue in the mouse [8] and in the human [9] GnRH-Rs.
This mutation, though identified in two nCHH families in two
independent series [6,7], has not been characterized. In these
families, the somehow afflicted individuals were heterozygous.
This observation is surprising as the frame shift GNRH1 mutation
only resulted in nCHH in homozygous patients [5].
Here we report on the identification of p.R31C mutation in
three individuals in two additional unrelated nCHH families. All
the individuals are heterozygous for the mutation. We have
undertaken a comprehensive molecular characterization of the
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mutation in order to understand the mechanism of nCHH in these
individuals.
Results
Genetic analysis
We identified the GNRH1 c.91C.T (p.R31C) mutation in two
unrelated French families with nCHH. Demographic, clinical,
biological and genetic data are reported in Table 1. Interestingly,
the two pedigrees are very different in terms of presentation
(Fig. 1). In family 1, nCHH is sporadic. The boy (II.1) presented at
19 years old with a failure to progress through puberty. At physical
examination he had a partial pubertal development with 12-mL
bilateral testes volume. He had no olfactory impairment.
Hormone assays revealed very low testosterone levels and low
gonadotropin levels. No secondary causes were found for central
hypogonadism (see Table 1). GNRH1 heterozygous mutation in
this boy was de novo, as ascertained by micro-satellites analysis.
In the second family the GNRH1 mutation was present in
heterozygosis and segregated with disease. The boy (II.1) was
diagnosed having hypogonadotropic hypogonadism because of
small testis volume (10 mL at left, 12 mL at right testis), low serum
testosterone and low gonadotropins. His pubertal stage was P3
according to Tanner. He had no anosmia. Common causes of
secondary hypogonadism were excluded. His mother (I.2) was
affected by primary amenorrhea, and conceived after ovarian
stimulation by exogenous gonadotropins, although a formal
diagnosis was not established at that time. She was re-evaluated
later at the age of 65, and hormone assays revealed low sex steroids
accompanied with inappropriately low gonadotropins. She had no
other apparent secondary causes (see Table 1). The father (I.1) was
not available for genetic analysis.
We did not identify a second genetic event after genomic
regulatory region analysis of GNRH1 locus and GNRH1 cDNA
sequencing in all propositii.
Predictive analysis
The GNRH1 c.91C.T nucleotide substitution did not create
any donor or acceptor aberrant splice site according to prediction
tools with AlamutH software. This nucleotidic substitution induces
a missense at codon 31, replacing Arginine-31 by a Cysteine in the
pre-pro-GnRH (GNRH1 p.R31C).
Figure 1. Pedigree of nCHH families carrying c.91C.T (p.R31[R, C]) GNRH1 mutation. In the family 1, the propositus (II.1) has a de novo
mutation and his filiation has been confirmed by DNA microsatellites. In the family 2 the mutation was transmitted from the mother (I.2) to her son
(II.1). She required medical assistance for procreation. Clinical and demographic data of all patients are reported in Table 1. Electropherogram
represents the heterozygous mutation in the individual II.1 from family 1. In the panel below, pre-pro-GnRH amino acid sequence conservation.
Decapeptide is shown in red.
doi:10.1371/journal.pone.0069616.g001
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Prop v.1.0b predicted that this missense did not abolish
proconvertase-dependent cleavage site for pre-pro-GnRH matu-
ration into the decapeptide (amino-acids 24 to 33).
Alignment with orthologs revealed conservation of arginine in
position 8 of GnRH in mammals (Fig. 1). This amino acid
exchange was classified as deleterious by various in silico prediction
tools (see methods section). More importantly, experiments on the
substitution of arginine 8 with a variety of amino acids
demonstrate that it is crucial for binding and signaling [10].
Arginine 8 was further shown by mutagenesis studies in the
GnRH-R that it interacted with an acidic residue in the
extracellular loop three of the mouse (glutamate 301) and the
human (aspartate 302) GnRH-Rs [8,9].
In vitro molecular characterization
R31C and wild-type (WT) decapeptides were stable over 24-
hours at room temperature in water and culture medium. No
dimerization of the mutant decapeptide was found (Fig. S1).
The R31C GnRH peptide bound the GnRH-R with an affinity
more than 100-fold lower than that of WT GnRH (Fig. 2A and
2B). Dose-response curves with SRE-luciferase assay showed an
almost 100-fold reduction of R31C agonist versus WT (Fig. 3A).
The EC-50 was 4 nM for WT GnRH and 314 nM for R31C
GnRH (p,0.0001, Fig. 3B). ERK1/2 phosphorylation was
maximal at 5 minutes. R31C GnRH showed similar kinetics,
but the degree of phosphorylation was reduced (Fig. 4A).
WT GnRH induced a rapid and transient calcium mobilisation
in LbetaT2 cells. Calcium response by R31C was significantly
reduced compared to WT in terms of peak and area under the
curve (p,0.05, see Fig. 5). Pre-treatment with 100 nM GnRH-
antagonist cetrorelix abolished responses to both ligands (data not
shown). The IP accumulation dose-response curve demonstrated
that the R31C GnRH (EC-50, 199 nM) was more than a 100-fold
less potent than WT GnRH (0.5 nM), (p,0.01, Fig. 6A and B).
The maximal IP generated by both ligands was the same
indicating that the R31C GnRH peptide was a full agonist, as
was found in the SRE-luciferase assay.
WT GnRH significantly increased lhb transcript levels in
gonadotropes (p,0.01), whereas R31C GnRH did not signifi-
cantly increase these levels over baseline (not significant, Fig. 7A).
WT GnRH strongly stimulated LH secretion over baseline
(p,0.001). R31C GnRH significantly stimulated LH secretion in
LbetaT2 cells supernatants over baseline (p = 0.042, Fig. 7B).
The above findings clearly show that in binding, signaling and
functional assays, the R31C GnRH is less potent than WT GnRH.
Since the heterozygous condition was associated with nCHH in
our patients, that could suggest a dominant negative effect, we
studied the effects of combining WT GnRH with R31C GnRH.
We hypothesized that the cysteine in position 8 of the R31C
GnRH might form disulfide bridges with cysteine residues in the
receptor that are not in disulfide bridges. There are three such
cysteines: cysteine 218, cysteine 279 and cysteine 317. In order to
examine this possibility the effects of R31C GnRH pre-incubation
on subsequent binding of a radio-labelled GnRH analog was
examined. We determined from the competition binding study
that R31C GnRH would occupy 50% of receptors. As a control,
we utilized WT GnRH at 1028 M, which also occupies 50% of
receptors. After treatment, the cells were extensively washed to
remove all non-covalently bound peptide. Subsequent binding of
radiolabeled GnRH analog was the same in these treatments as
well as in medium-treated cells (Fig. 2B). These findings indicate
that both WT GnRH and R31C GnRH can be fully removed
from the receptor, indicating that R31C GnRH does not form
covalent disulfide bonds with the receptor.
Dose-response curves generated from SRE-coupled luciferase
were indistinguishable from WT GnRH administered alone
(Fig. 3A).
Table 1. Clinical, biological and genetic characterization of
patients.
II.1
(Family 1)
II.1
(Family 2)
I.2
(Family 2)
Clinical data
Sex M M F
Age at diagnosis 19 21 65
Total testosterone (ng/mL) * 0.8 0.77 NA
Estradiol (pg/mL) * NA 7 ,12
LH (mU/mL) * 1 1 2.8
FSH (mU/mL) * 0,9 1.4 5.8
LH pulsatility NA Absent NA
AMH (mmol/l) * NA 1.4 ,0.4
Inhibin B (ng/mL) * NA 101 ,15
Ferritin (mcg/mL) 63 56 103
Testicular volume (mL) 12 10 -
Ovarian volume (mL) - - ,10
Pituitary and olfactory IRM Normal 3-mm Rathke’s
cyst
Normal
Olfactometry** Normal Normal Normal
Associated features None None None
Genetic data
GNRHR1 normal normal normal
KISS1 normal normal normal
GPR54 normal normal normal
PROK2 normal normal normal
PROKR2 normal normal normal
FGFR1 normal normal normal
FGF8 normal NA NA
NELF NA normal normal
TAC3 normal normal normal
TACR3 normal normal normal
GNRH1 promoter normal normal normal
GNRH1 exon 1 normal normal normal
GNRH1 intron 1 normal normal normal
NA: not available.
*Reference ranges for hormone levels and method characteristics. Total
testosterone: 3.5–8.5 ng/mL for adult men (RIA, Orion Diagnostica device,
SpectriaH, Espoo, Finland; detection limit: 0.01 ng/mL; intra- and interassay
coefficients of variation (CVs): 3.2% and 4.6%); estradiol: 15–35 pg/mL for men,
,16 for post-menopausal women (RIA, Orion Diagnostica, SpectriaH; detection
limit: 2 pg/mL; intra- and the interassay CVs: 2.8% and 5.8%); LH: 1.4–8 mU/mL
for men, .30 mU/mL for post-menopausal women; FSH: 1.4–10 mU/mL for
men, .30 mU/mL for post-menopausal women (for LH and FSH: Immunotech
device, Beckman Coulter, Praha, Czech Republic; detection limits: 0.1 IU/L for
both FSH and LH; intra- and interassay CVs:,6.3% for FSH,,6.7% for LH); AMH:
22–38 pmol/L for men, 14–48 for women (enzyme immunometric assay,
Immunotech reagents, Beckman Coulter Company, Marseille, France; detection
limit: 0.4 pmol/L; intra and interassay CVs: ,12.3% and ,14.2%,); Inhibin B: 80–
327 pg/mL for men, ,20 pg/mL for post-menopausal women (enzyme
immunometric assay, Oxford Bio-Innovation reagents, Serotec, Oxford, UK;
detection limit: 15 pg/mL; intra- and interassay CVs: 4.2% and 10.2%,).
**Subjective olfactometry was performed by a computed-assisted validated test
[35].
doi:10.1371/journal.pone.0069616.t001
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After pulsatile administration of each ligand at 90-minute
frequency, WT GnRH was more potent than R31C GnRH to
induce luciferase activity coupled to SRE reporter gene. Combi-
nation of WT and R31C was not able to impair luciferase activity
when compared to WT alone (Fig. S2).
Treatment of LbetaT2 and GnRH-R-expressing HEK293T
cells with 10 nM WT GnRH in combination with 10 nM R31C
GnRH induced similar kinetics of ERK1/2 phosphorylation
compared to 10 nM WT alone (Fig. 4A). Increasing the dose of
R31C GnRH from 10 nM to 300 nM in the presence of 10 nM
WT GnRH did not reduce ERK1/2 phosphorylation at 5 minutes
exposure (Fig. 4B). Calcium peak and area under the curve after
treatment with the combination of 10 nM GnRH and 10 nM
mutant peptide was indistinguishable from WT GnRH alone
(Fig. 5). IP dose-response curve with equal concentrations of WT
and R31C peptides was indistinguishable from WT GnRH alone
Figure 2. Binding of WT and R31C GnRH to the GnRH receptor (GnRH-R). (A) COS-7 cells were transiently transfected with a human GnRH-R
DNA construct and incubated with a 125I-labeled GnRH agonist in the presence of indicated concentrations of WT GnRH or R31C GnRH. IC-50 values
are WT GnRH, 2.861029 M and R31C GnRH, 8.5061027 M. Data are given as means and SD of two experiments performed in duplicate. (B)
Transfected COS-7 cells were pre-incubated with buffer alone, WT GnRH (1028 M) or R31C GnRH (1025 M) and then washed to allow dissociation of
ligand not covalently attached to the GnRH-R. Pre-incubated cells were then incubated with 125I-labeled GnRH agonist in the absence or presence of
saturating concentration of unlabeled WT GnRH (NSB). Data are the means of two experiments performed in triplicate.
doi:10.1371/journal.pone.0069616.g002
Figure 3. SRE-coupled luciferase assay. (A) HEK293T cells were exposed to graded concentrations of wild type (WT) GnRH, R31C and equimolar
concentrations of WT + R31C during five hours. Luciferase activity arbitrary units by luminometry (a.u.) have been shown as ratio on beta-
galactosidase activity by optical density used as transfection efficiency internal control. This experience was conducted eight times. (B)
Representation of individual values of EC-50 (calculated with Arcsin ‘‘P’’ root transformation) from n=8 dose-response experiments. WT GnRH EC-50
was calculated at 461.2 nM, R31C EC-50 at 3136130 nM. ***p,0.0001.
doi:10.1371/journal.pone.0069616.g003
R31C GNRH1 Mutation in Hypogonadism
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e69616
(Fig. 6). This indicates that a full range of doses of R31C GnRH
does not influence the ability of WT to bind and activate the
GnRH-R. R31C GnRH was also unable to influence the
stimulation of lhb transcription (Fig. 7A) or LH secretion (Fig. 7B)
from LbetaT2 cells by WT GnRH.
Discussion
GNRH1 mutations are a very rare cause of nCHH [5–7,11,12].
The GNRH1 p.R31C mutation is the only description of an amino
acid change in GnRH. Yet this mutation has been described in
nine individuals in four separate families. This mutation was first
reported in association with nCHH in heterozygosis and a
dominant inheritance was postulated [6], contrasting with the
previously described recessive transmission of the frame shift
mutation, which fails to transcribe the GnRH sequence [5]. Some
nCHH individuals with the R31C mutation concomitantly had
variations in other nCHH genes perhaps suggesting oligogenism.
More recently, the R31C mutation was reported in a girl with no
variations in other nCHH and Kallmann Syndrome-related genes
[7]. This is of interest since this study analyzed all known genes
associated with nCHH and Kallmann Syndrome aiming to
establish the prevalence of oligogenism in these syndromes. This
mutation was considered not sufficient to explain the phenotype
because of the heterozygous inheritance [7]. In the present study,
we have found the same mutation in three additional nCHH
patients from two unrelated families and unrelated to the
previously described families with the R31C mutation. Although
sex steroid and gonadotropin levels undoubtedly related to CHH,
more-than 4 mL testicular volume in patients at presentation
suggested a residual functional activity of hypothalamic-pituitary-
gonadal axis, probably reflecting heterozygosity.
The identification of this recurrent mutation in four unrelated
families, the finding of a de novo event in one family and the
location of the nucleotide base change within a CpG islet are three
consistent arguments for a mutational «hot spot». As interest, this
amino acid is the most variable among vertebrate and invertebrate
GnRHs [1–4]. The R31C GnRH mutation has never been
identified in controls and segregation with the phenotype has been
found in all affected families (see Table 2). Furthermore, this
nucleotide base change has not been identified in 5989 individuals
from the Exome Sequencing Project (ESP) cohort (NHLBI GO,
Seattle, WA; URL: http://evs.gs.washington.edu/EVS; October,
2012). Thus, this implies that this missense mutation is likely
responsible for the nCHH phenotype. However, although the
R31C GnRH had very low activity in receptor binding, SRE-
luciferase, IP, Ca2+, ERK1/2 signaling and in lhb gene expression
and LH secretion, we were unable to demonstrate any dominant
negative effect on WT GnRH activities.
Previous genetic studies established that GNRH1 loss of function
mutations lead to an autosomal recessive nCHH. Thus we first
searched for another genetic event at GNRH1 locus. This was
excluded by an exhaustive analysis of the entire sequence of intron
1 present in the hypothalamic primary transcript, the sequence of
the upstream and downstream GNRH1 promoters and the cDNA
coding regions [13,14]. We also ruled out oligogenism by
sequencing the main genes associated with nCHH and Kallmann
Syndrome [15–17], although WDR11, CHD7 and SEMA3A, other
genes known to be associated with CHH, have not been analyzed.
Furthermore, we cannot entirely exclude the contribution of a
gene not known to be associated with CHH. Next generation
Figure 4. ERK1/2 phosphorylation by Western blot. (A) LbetaT2 cells were starved overnight in serum-free DMEM and then treated by 10 nM
WT, 10 nM R31C, 10 nM WT +10 nM R31C peptides or vehicle for 0, 5, 10 and 30 minutes. Representative of four experiments. Density quantification
is displayed on right-hand, and data are expressed as mean 6 SD for four experiments. *p,0.05; **p,0.01 over baseline. (B) LbetaT2 cells were
starved overnight in serum-free DMEM and then treated by a constant dose of WT GnRH (10 nM) and increasing (0–10–300 nM) doses of mutant
R31C peptide after 5 minutes exposition. Lysates were analyzed by Western Blotting using phospho-ERK1/2 antibodies (Cell SignalingH, open arrow)
and mouse monoclonal anti alpha-tubulin (Sigma AldrichH, St. Louis, MO, close arrow). Similar results on ERK intensity and kinetics were obtained
using transiently transfected HEK293T cells.
doi:10.1371/journal.pone.0069616.g004
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sequencing methods could be helpful to find a possible second
genetic defect.
In order to investigate the possible mechanisms whereby R31C
GnRHmight influence the actions ofWTGnRH, as it is apparently
the case in the patients, we set about first examining the activity of
the R31C GnRH in receptor binding and variety of signaling
pathways, as well as its ability to stimulate LH release. We then
examined its ability to affect WT GnRH actions in these systems.
R31C GnRH had a binding affinity of more than 100-fold lower
than that of WT GnRH. Consistent with this observation, R31C
GnRH had similar reductions in potency (increased EC-50 values)
in stimulation of SRE-luciferase and IP generation.However, R31C
GnRH was able to elicit the same maximal stimulation of SRE-
luciferase and IP, clearly demonstrating that it is a full agonist in
recruiting these signaling pathways. This indicates that it has no
antagonistic activity and it is therefore unlikely to explain the
phenotype of the heterozygous patients. Supporting these observa-
tions, R31C peptide determined weaker responses in contrast to
those of WT GnRH on ERK1/2 phosphorylation, Ca2+ mobiliza-
tion, lhb transcription and LH secretion.
Further studies confirmed our interpretation that R31C GnRH
does not antagonize WT GnRH actions at the receptor level.
When R31C GnRH, at concentrations varying from 10210 M to
1026 M, was added in combination with WT GnRH at 1029 M in
various experiments, it failed to have any impact on receptor
binding, SRE-luciferase, IP generation and Ca2+ signaling or on
lhb transcription and LH secretion. These findings are in
accordance with our understanding of structure-activity relations
of GnRH analogs and their interaction with the GnRH-R.
Arginine 8 is crucial for the correct conformation of mammalian
GnRH and for its binding to the receptor [1–4]. In particular
arginine 8 has been demonstrated to be crucial for the interaction
with the aspartate 302 of the human GnRH-R and the glutamate
301 of the mouse GnRH-R [8,9,18].
The mode of inheritance, apparently dominant in four families,
is thus not explained by a simple negative dominance in the
parameters that we have measured. There are other possibilities
that were not investigated here. Firstly, the mutant peptide may
interact with molecules within the GnRH neuron to impair
activity or induce toxicity, thereby reducing WT GnRH secretion.
Aberrant transcription products might be retained in the
endoplasmic reticulum or could act as neurotoxic agents, as
already demonstrated for pro-dynorphin in ataxia [19] or
arginine-vasopressin variants in diabetes insipidus [20]. Another
Figure 5. Effect of treatments on intracellular calciummobilization. Cells were loaded with Fura 2-AM. At the time of the experiment 100 mM
EGTA was added 30 sec before addition of 300 mM of CaCl2 (Ca2+) to the medium as indicated, and cells were then stimulated with 10 nM of wild
type (WT), mutant (R31C) or equimolar combination (10 nM WT +10 nM R31C) or vehicle for 3 min. In the upper panel, representative curves of single
cell recording. Each experiment mean was analysed using One-way ANOVA followed by Tukey’s Multiple comparison test. In the lower panels,
histograms show the means 6 SEM (n= 4) of the response to ligands as calcium peak and as area under the curve (AUC). R31C-induced peak and
AUC were significantly lower than WT. Combined treatment by WT+R31C did not induce a different calcium peak and AUC compared to WT alone.
Representative of at least three independent experiments, *p,0.05.
doi:10.1371/journal.pone.0069616.g005
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possibility is that, in GnRH neurons, the R31C GnRH precursor
forms an aberrant intermolecular disulfide bridge with the WT
GnRH precursor, which disrupts correct folding of the molecule
leading to detection by surveillance proteins and trafficking to
lysosomes for degradation of both peptides. In addition, the
heterodimer may be resistant to processing.
Although a wide range of cellular models was used, they do not
necessarily reflect in vivo events. Despite abundant literature, the
molecular mechanisms underlying GnRH-R down-regulation and
pulse deciphering remain currently poorly understood [21–23]. It
is of note that SRE-luciferase activity was not impaired after four
pulses at 90-minute frequency (Fig. S2). Nevertheless a slow and
progressive loss of pituitary response to mutant GnRH might
require a longer pulsatile exposure. In this context, a transgenic
mouse model may shed light on the mechanism of the dominant
negative effect [24].
In conclusion, together with our report, four nCHH families
carrying R31C GNRH1 heterozygous mutations have been
identified. As this is a putative «hot spot» mutation it is likely to
be identified in other nCHH families. The families harboring the
R31C mutation are of great interest for reproductive sciences since
the pathophysiology is not explained by in vitro experiments. There
is herein an obvious opportunity to study novel aspects of GnRH
signaling in vivo and/or to identify novel genes modulating GnRH
reproductive function.
Materials and Methods
Patients
From a cohort of 410 patients with congenital hypogonadism
we screened for a panel of mutations including GNRH1 (see
below). The study was approved by the Paris Sud University
Hospital ethics committee and complied with human research
guidelines as stated in the Declaration of Helsinki. Patients gave
their written informed consent before genetic analysis and
hormone studies.
Hormone assays
Serum LH, FSH, inhibin B, plasma testosterone and estradiol
concentrations were measured by immunoradiometric, enzyme-
linked immunoabsorbent, or radioimmuno-assays [25] as reported
in Table 1.
Genetic testing
Genomic DNA was isolated from white blood cells (WBC).
Direct genomic sequencing of GNRH1 was performed by
sequencing all exons and exon-introns junctions (NG_016457.1),
up-stream and down-stream promoter encompassing 1100 bp
before start site of transcription (Fig. S3). Direct genomic
sequencing of coding exons and intron-exon junctions of
GNRHR1, KISS1, GPR54, NELF, TAC3, TACR3, FGF8, FGFR1,
PROK2 and PROKR2 was performed as previously described [26].
PCR primers were designed by Primer Blast (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/) [26]. PCR and sequencing
products were purified on a Biomek NXP-96 Laboratory
Automation Workstation (Beckman Coulter, Villepinte, France)
with Agencourt Ampure XP and Agencourt Cleanseq (Beckman
Coulter Genomics, Danvers, MA). Sequencing products were
analyzed with an automated capillary sequencer (ABI PRISM
3130xl Genetic Analyzer; Applied Biosystems, Foster City, CA).
Electropherogram-derived sequences were compared with NCBI
references using SeqScape Software 2.6 (Applied Biosystems,
Foster City, CA).
Figure 6. IP accumulation. (A) COS-7 cells were transiently transfected with human GnRH-R expression vector and washed before the addition of
myo-[2-3H]Inositol. After 16 hours cells were washed and incubated for 1 hour with graded concentrations of WT, R31C and equimolar WT+R31C
GnRH. This experience was conducted three times each in triplicate. (B) Representation of individual values of EC-50 (calculated with Arcsin ‘‘P’’ root
transformation) from n= 3 dose-response experiments. WT GnRH EC-50 was calculated at 0.5260.22 nM, R31C EC-50 at 198.8675.9 nM, WT+R31C
EC-50 at 0.6360.42 nM.
doi:10.1371/journal.pone.0069616.g006
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Microsatellites genotyping was performed to confirm filiation
(Powerplex 16 SystemH, Promega, Madison, WI).
Total RNA was extracted from cells (WBC or cells in culture)
with the TrizolH reagent (InVitrogen, Cergy Pontoise, France).
RT-PCR and direct cDNA sequencing was performed as
previously reported [26,27]. Complete CDS of GNRH1 transcripts
(NM_0001083111.1 and NM_000825.3) were analyzed with
primers for RT-PCR and sequencing in Table S1.
Molecular Characterization of the GnRH R31C mutant
Peptide custom and stability. ‘‘Wild type’’ (pGlu-His-Trp-
Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) and ‘‘R31C’’ (pGlu-His-Trp-
Ser-Tyr-Gly-Leu-Cys-Pro-Gly-NH2) mutant GnRH were synthe-
sized by a custom peptide manufacturer (EurogentecH, Lie`ge,
Belgium). Molecular weight was confirmed by MALDI-TOF and
purity was assessed at ,95% by the manufacturer.
Lyophilized products were suspended in sterile water in order to
obtain 0.1 mM aliquots and conserved frozen at 2150uC.
LC-MS/MS was performed with Quattro-LCZ triple quadru-
pole mass spectrometer equipped with the orthogonal electrospray
source (Micromass,Manchester, UK) to analyze peptides stability in
solution. Peptides solutions (water and cell culture medium) were
incubated 24-h at room temperature for these stability studies.
In silico prediction of peptide cleavage was performed by means
of Prop v.1.0b ProPeptide Cleavage Site (http://www.cbs.dtu.dk/
services/ProP).
Prediction of protein function after selective amino acid
substitution was obtained by means of AlamutH (Interactive
Biosoftware, Rouen, France), AlignGVD (http://agvgd.iarc.fr/
agvgd_input.php/), Polyphen2 (http://genetics.bwh.harvard.edu/
pph2/), SIFT (http://sift.jcvi.org/) and PANTHER Coding SNP
Analysis tool (http://www.pantherdb.org/tools/csnpScoreForm.
jsp).
Cell lines
Various cell lines were used for the experiments. HEK293T
(ATCC CRL-11268) and COS-7 (ATCC CRL-1651), which do
not express GnRH-R, were used after transient transfection with
expression vector of human GNRHR (Missouri S&T cDNA
Resource Center, Rolla, MO). Murine gonadotrope LbetaT2
cells were kindly provided by Dr. Mellon laboratory [28]. These
cells endogenously express GnRH-R and are able to express
gonadotropin subunit transcripts and to secrete mature LH
glycoprotein after GnRH treatment [28].
Competition radioligand binding assays
The high affinity GnRH analog, [His5, D-Tyr6]-GnRH was
radio-iodinated as previously described [29] and purified using
Sephadex chromatography [30]. COS-7 cells were transiently
transfected with a human GnRH-R DNA construct containing the
human GnRH-RII carboxy-terminal to enhance expression [31]
using 6 mg of DNA and 30 ml FuGene HD (Promega Corporation,
Madison, WI) per 10 cm dish and seeded into 12-well plates. Two
days after transfection cells were washed with HEPES-DMEM
containing 0.1% bovine serum albumin (261 ml, HEPES-
DMEM-BSA) and incubated with 125I-[His5, D-Tyr6]-GnRH
(100,000 CPM per well) and various concentrations of WT GnRH
or R31C GnRH (4 h, 4uC) in a total volume of 0.5 ml. Cells were
washed with phosphate-buffered saline (261 ml) and lysed with
NaOH (1 ml, 0.1 M). Cell-bound radioactivity was counted in a
gamma counter and IC-50 values were calculated using Graphpad
Prism (GraphPad Software Inc, San Diego).
To determine whether R31C GnRH binds covalently to the
GnRH-R, transfected COS-7 cells were incubated with WT
GnRH (1028 M), R31C GnRH (1025 M) or HEPES-DMEM-
BSA alone (2 h, 4uC), washed with HEPES-DMEM-BSA (1 ml)
and incubated in HEPES-DMEM-BSA (5 ml, 1 h, 4uC) to allow
Figure 7. Effects of treatments on lhb transcription and LH
secretion. (A) LbetaT2 cells were starved overnight in serum-free
DMEM and treated either by 10 nM WT, R31C, 10 nM WT +10 nM R31C
peptides or vehicle. After five hours treatment cells were lysed for RNA
extraction (TrizolH). Mouse lhb levels were analyzed by quantitative real
time RT-qPCR. Values are expressed as individual ratios on 18S and
represented as fold induction on vehicle as means 6 SEM, **p,0.01.
This experience was conducted n= 7 times in duplicates. (B) LH
concentrations from LbetaT2 cells culture media. Cells were starved
overnight in serum-free DMEM and incubated with 10 nM WT, 10 nM
R31C, 10 nM WT +10 nM R31C, or vehicle for 5 hours. LH levels were
measured by a combined rat/mouse RIA. Values are expressed as
individual values and as means 6 SEM, *p,0.05, ***p,0.001. The
experiment was conducted four times and each sample was assayed in
duplicates.
doi:10.1371/journal.pone.0069616.g007
Table 2. Recurrence of c.91C.T (p.R31C) GNRH1 base change
in subjects from CHH families and in healthy controls.
Authors Reference Year CHH
Healthy
individuals
Vagenakis et al. [11] 2005 0/26 NA
Chan et al. [6] 2009 4/310 0/192
Topaloglu et al. [36] 2009 0/50 0/100
Quaynor SD. et al. [7] 2011 2/48a 0/188
Current study 2013 3/410b 0/545b
Total 9/844*** 0/1025
NA: not applicable; *** p,0.0001 by Fisher’s test between CHH patients and
healthy controls. a: the mother of the female propositus has been represented as
a carrier but no clinical data are reported. b: 120 CHH patients and 345 healthy
subjects have been added to previously published data [5].
doi:10.1371/journal.pone.0069616.t002
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dissociation of non-covalently bound peptide, before the binding
assay was performed as above.
Serum Responsive Element (SRE) luciferase assay
luc2P/SRE/Hygro plasmid (Promega, Madison, WI) was used
to test luciferase production in response to MAP kinase activation
as a reporter gene system. HEK293T cells (1.26104 cells/well)
were seeded 72 h before testing in high-glucose Dulbecco’s
minimal essential medium (DMEM, Invitrogen, Cergy Pontoise,
France) containing 2 mM glutamine, 100 IU/mL penicillin,
100 mg/mL streptomycin, and 10% heat-inactivated fetal calf
serum at 37uC in 96-well plates. Twenty-four hours before
testing, cells were co-transfected in serum free OptiMEM, using
Lipofectamine 2000 (Invitrogen, Cergy Pontoise, France) with
the plasmids for human GnRH receptor, luc2P/SRE/Hygro and
pMIR-REPORTTM beta-galactosidase vector (Applied Biosys-
tems, Foster City, CA). WT GnRH, R31C, WT+R31C or
vehicle were added at different dilutions (from 10210 to 1026 M).
After 5 h-incubation cells were harvested and assayed for
luciferase activities as previously described [32], using a
luminometer (Victor, Perkin Elmer, Waltham, MA). To stan-
dardize for transfection efficiency, the relative light units were
normalized by the galactosidase activity at optical density. EC-50
and Emax values were calculated using Graphpad Prism
(GraphPad Software Inc).
Inositol phosphate (IP) accumulation
COS-7 cells were transiently transfected by electroporation with
human GnRH-R DNA (10 mg/15 cm dish), seeded into 12-well
plates and radiolabelled by overnight incubation with myo-
[3H]Inositol (0.5 mCi/well, American Radiolabeled Chemicals, St
Louis,Mo).Radiolabelled cells werewashed and incubated (30 min,
37uC) in IP medium (HEPES-DMEM-BSA supplemented with
10 mM LiCl), then stimulated (60 min, 37uC) with various
concentrations of WT GnRH or R31C GnRH or equal concentra-
tions ofWTGnRHandR31CGnRH. Incubations were stopped by
removal of the medium and cells were lysed by addition of formic
acid (1 ml, 10 mM). IP were extracted from cell lysates usingDowex
1 X8-200 chromatography and counted using a liquid scintillation
counter (Pack ard). EC-50 and Emax values were calculated using
Graphpad Prism (GraphPad Software Inc) [33].
ERK1/2 Western blot
LbetaT2 cells were starved 18 h in serum-free DMEM before
treatments, then exposed to 10 nM of WT, 10 nM of R31C, the
combination of 10 nM of each peptide or vehicle. Cells were
harvested at 0, 5, 10, 15 and 30 minutes after treatment. Western
blotting analyses were performed as previously described [32].
Measurement of intracellular free calcium concentration
([Ca2+]i)
LbetaT2 cells were kept in serum freemediumovernight and then
loaded with 2 mM Fura2-AM for 45 min at 37uC. The experiment
was conducted in HEPES buffer (in mM; 116 NaCl, 5.6 KCl, 1.2
MgCl2, 5 NaHCO3, 1 NaH2PO4, 20 HEPES ph 7.4) in presence of
extracellularCa2+ (EGTA100 mM+CaCl2 300 mM). Single images
of fluorescent emission at 510 nm under excitation at 340 and
380 nm were taken every 5 Sec. Changes in [Ca2+]i in response to
GnRHs were monitored using the Fura2 340/380 fluorescence
ratio. Basal ratio was arbitrarily considered as 1. Ca2+ responses over
basal level were given either as maximal rise of [Ca2+]i or as area
under the curve (for 2 min after agonist addition).
Gene expression study
LbetaT2 cells were grown at 106/well in 6-well plates and
starved in serum-free DMEM 18 h before tests. After 5 hours
incubation with 10 nM WT, R31C, the combination of 10 nM
WT +10 nM R31C peptides or vehicle, cells were washed with 16
PBS and total RNA isolated using TrizolH (Invitrogen, Germany).
Lhb (murine LH beta subunit) transcript was quantified by real-
time RT-PCR, using an ABI Step One Sequence Detector
(Applied Biosystem, Foster City, CA) as previously described [27].
Primers are provided in Table S1.
LH assay
LbetaT2 cells were starved overnight in serum-free DMEM.
The test day cells were exposed to 10 nM WT, R31C, the
combination of 10 nM of each peptide or vehicle during five
hours. Cell culture supernatants were collected and rapidly stored
at 280uC. In cell culture media, LH concentration was measured
using a previously described ELISA method [34] with reagents
supplied by Dr. Parlow (National Hormone and Peptide Program,
Harbor-UCLA Medical Center, Torrance, CA). The minimum
detectable LH concentration was 0.2 ng/ml, and the interassay
coefficient of variation was less than 10%.
Statistical analyses
Only nonparametric tests were used. Friedman’s test was used
to compare three or more matched groups and Kruskall-Wallis
test for unmatched groups. These analyses were followed by
Dunn’s post comparison test. Differences were significant when
p,0.05 (*p,0.05, **p,0.01, ***p,0.001). Statistical analyses
were performed using GraphPad Prism version 5.0d (GraphPad
Software Inc., San Diego, CA).
Supporting Information
Figure S1 Peptide stability on mass spectrometry-
coupled electrospray (Quattro-LC). Peptides were measured
in aqueous solution at pH 7 and starved overnight at 37uC. WT
and R31C decapeptides are found at the expected molecular
weights (1181.6 and 1128.5, respectively). Formation of smaller
fragments was absent in WT and negligible in R31C. Formation of
R31C dimers was absent.
(PPT)
Figure S2 Luciferase activity after pulsatile exposure.
HEK293T cells were transiently transfected with GNRHR and
SRE-coupled luciferase reporter gene, and then exposed to four
90 min-spaced pulses of 10 nM WT, 10 nM R31C and
10+10 nM WT+R31C. After 5 minutes exposure to each ligand,
cells were washed, and a subsequent pulse was given 90 minutes
after. Five hours after the last pulse, cells were harvested for
luciferase assay. Luciferase activity arbitrary units obtained by
luminometry (a.l.u.) are shown as ratio on beta-galactosidase
activity by optical density (used as transfection efficiency internal
control). This experience was conducted three times (n = 8
replicates for each experiment).
(PPT)
Figure S3 Genomic localization of human GNRH1 and
related transcription and translation products. Two main
regulatory regions are located upstream the trascription start site:
the proximal promoter mainly regulates hypothalamic trascript,
whereas the distal promoter controls a longer GNRH1 transcript
(retaining entire intron 1 sequence) in the extra-cerebral tissues.
Amino acids are represented by letters from the international
nomenclature. In the prepropeptide GnRH, functional domains
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are represented for the signal peptide (23 amino acids, blue),
decapeptide GnRH (purple), and GnRH-associated peptide (GAP)
(56 amino acids, green) (adapted from Bouligand et al., NEJM,
2009).
(PPT)
Table S1 Primer sets used for experiments.
(DOC)
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